FDA proposes excluding Novo, Lilly GLP-1s from compounding list

The ⁠Food and Drug ⁠Administration on Thursday proposed ​excluding the active ingredients in Novo Nordisk ‌and Eli Lilly‘s blockbuster obesity and diabetes medications from the ⁠list ⁠of drugs that outsourcing facilities can use for ​compounding in bulk.

If that proposal is finalized, the exclusion would likely limit the mass compounding — or the making of custom, often cheaper alternatives — of those medicines ​unless they appear on the FDA’s ⁠drug shortage ⁠list. The agency said it will consider public comments, which can be submitted until late June, before making a final decision.

The FDA finds “no clinical need” for outsourcing facilities to compound them from bulk drug substances, the agency said in a release.

The proposal includes semaglutide, the active ingredient in Novo’s obesity drug Wegovy and diabetes counterpart Ozempic, and tirzepatide, which is in Lilly’s weight loss injection Zepbound and diabetes shot Mounjaro. It also covers ⁠Novo’s older molecule liraglutide.

“When FDA-approved drugs are available, ​outsourcing facilities cannot lawfully ​compound ⁠using bulk drug substances unless there is a clear clinical ⁠need,” ​FDA Commissioner Marty ​Makary said in the release.

The agency’s proposal specifically targets 503B outsourcing facilities, which manufacture compounded drugs in bulk with or without prescription and are largely regulated by FDA guidelines. 

The proposal does not impact 503A pharmacies, which make compounded drugs according to individual prescriptions for a specific patient and are largely regulated by states rather than the FDA. 

Lilly and Novo have invested billions to ramp up manufacturing capacity over the last several years, which has helped alleviate supply constraints. The companies have also pursued efforts to make their branded medications more affordable to win over users who had flocked to cheaper compounded medications.